Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744256 | PMC |
| http://dx.doi.org/10.1172/jci.insight.165502 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CD2 expressing innate lymphoid and T cells are critical effectors of immunopathogenesis in hidradenitis suppurativa.
Proc Natl Acad Sci U S A
November 2024
Center for Epigenomics and Translational Research in Inflammatory Skin Diseases, University of Alabama at Birmingham, Birmingham, AL 35294.
Article Synopsis
- Hidradenitis suppurativa (HS) is identified as a chronic inflammatory skin disease characterized by an increase in CD2-expressing lymphocytes and T cells in affected skin areas.
- CD2+ cells, primarily innate lymphocytes and CD4 T cells, interact with keratinocytes and fibroblasts, highlighting their role in the disease's unique skin dynamics.
- Blocking the CD2:CD58 interaction may reduce inflammation and suggests a promising immunotherapeutic strategy for managing HS.
[Monoclonal antibodies for inflammatory, autoimmune and oncological skin diseases].
Dermatologie (Heidelb)
October 2024
Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.
In 1997 rituximab, a genetically engineered chimeric monoclonal antibody (mAb) targeting CD20 expressed on B cells was approved for treatment of non-Hodgkin's lymphoma. Since then, pharmacological improvements combined with increased knowledge on the immunopathogenesis of diseases led to the development of specific mAb targeting different antigens (e.g.
View Article and Find Full Text PDFBiologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review.
Children (Basel)
July 2024
Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
Article Synopsis
- The management of pediatric dermatological conditions has advanced with new biologics and small molecule therapies, originally approved for adults but now being evaluated for children and adolescents.
- The review aims to summarize recently FDA-approved and potential therapies for conditions like alopecia areata, psoriasis, atopic dermatitis, and hidradenitis suppurativa in pediatric patients.
- Key findings include FDA-approved treatments such as ritlecitinib for alopecia areata and multiple biologics for pediatric psoriasis and atopic dermatitis, with several others undergoing phase 3 clinical trials for potential approval.
Therapeutic Potential of IL-1 Antagonism in Hidradenitis Suppurativa.
Biomolecules
February 2024
Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
The immunopathogenesis of HS is partially understood and exhibits features of an autoinflammatory disease; it is associated with the potential involvement of B cells and the contribution of Th1 or Th17 cell subsets. Recently, the pathogenic role of both innate immunity and IL-1 family cytokines in HS has been deeply investigated. Several agents targeting the IL-1 family pathway at different levels are currently available and under investigation for the treatment of HS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!